Terns Pharmaceuticals Inc.
Terns Pharmaceuticals Amends Exclusive License Agreement with Hansoh
Summary
On January 16, 2026, Terns Pharmaceuticals, Inc. amended its existing Exclusive Option and License Agreement with Hansoh. The amendment grants Terns Pharmaceuticals an exclusive, royalty-bearing, sublicensable, perpetual, and worldwide (excluding mainland China, Taiwan, Hong Kong, and Macau) license for certain patents related to TERN-701, in exchange for a $1.0 million upfront fee and tiered royalties. This amendment replaces a previous non-exclusive, royalty-free license granted to a subsidiary of Terns Pharmaceuticals.
Profitelligence Alerts
Get alerts for TERN
Be first to know when Terns Pharmaceuticals Inc. files with the SEC.
Filing Categories
Advertisement
About Terns Pharmaceuticals Inc.
Terns Pharmaceuticals Inc. is a biopharmaceutical company dedicated to the discovery and development of novel therapeutic candidates targeting liver disease and oncology. Its primary function is to advance its pipeline of clinical and preclinical drug candidates that address significant unmet medical needs. One of the company's main focuses is on non-alcoholic steatohepatitis (NASH), a progressive liver disease. Through innovative approaches, Terns Pharmaceuticals explores various mechanisms to treat NASH, including small molecules designed to reduce liver inflammation and fibrosis. Beyond liver disease, the company is expanding its platform to include oncology, diversifying its impact in the healthcare industry. As a key player in the biopharmaceutical sector, Terns Pharmaceuticals Inc. contributes to the growing landscape of targeted therapies. With a dedicated emphasis on research and development, the company plays an essential role in pushing the boundaries of treatment options, potentially transforming the management of chronic liver diseases and cancer.
Official SEC Documents
Advertisement